Physician profile
Norah Lunga
NPI 1215681630
$3,678.34
in general payments reported to CMS, 2019-2025
19 companies · $1,315 in 2025
The $1,315 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $224 · 2023: $1,001 · 2024: $1,138 · 2025: $1,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,454.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $595.82 | 2023-2025 | |
| Corium, LLC | $386.00 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $360.74 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $351.62 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $333.86 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $304.56 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Lundbeck LLC | $233.43 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Tris Pharma INC | $174.47 | 2024-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $173.41 | 2023-2025 | Caplyta |
| Alkermes, INC. | $167.65 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Ironshore Pharmaceuticals INC. | $140.50 | 2022-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $137.12 | 2024-2025 | Fanapt, Hetlioz |
| Indivior INC. | $124.90 | 2022-2024 | Perseris |
| Neurocrine Biosciences, INC. | $74.36 | 2024-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $37.08 | 2025 | Cobenfy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $28.49 | 2025 | Qelbree |
| Noven Therapeutics, LLC | $19.90 | 2025 | Xelstrym, Secuado |
| Collegium Pharmaceutical, INC. | $17.31 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $17.12 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norah Lunga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.